Exhibit 10.30



Pierpoint Investissements SA                                      June 25th 2004
Trident Chambers
P.O. Box 146
Tortola
British Virgin Islands

GenoMed, Inc.
909 S. Taylor Ave.
St. Louis, MO 63110
United States of America

AMENDED OFFER TO GENOMED INC.

This offer if accepted by GenoMed Inc.  completely  replaces  the current  offer
made to GenoMed  Inc. by  Pierpoint  Investissements  SA and accepted by GenoMed
Inc. on March 2nd 2004. The amended passages are highlighted in bold, below.

OVERVIEW

Pierpoint  Investissements  SA are  interested  in  purchasing  a minimum of USD
500,000 up to a maximum of USD 2 million  worth of common,  12-month  restricted
shares in GenoMed  Inc.  each and every year for a period of ten years at the 30
day market average (mid price of the bid and ask) less a discount of 25% for the
right to a total of 40 million  warrants  in GenoMed  Inc.  with a strike  price
being the 30 day market average (mid price) less a discount of 40%

OFFER TERMS

1. For the first  year  only  Pierpoint  Investissements  SA will  purchase  USD
225,000  worth of shares in GenoMed  Inc.  at USD 0.045  cents and a further USD
275,000 worth of shares at the 30 day market average (mid price) less a discount
of 25% by no later than  February  18th 2005.  Completion  of this  payment will
enable  Pierpoint  to be eligible  to a total of 40 million  warrants in GenoMed
Inc.  with a strike price being the 30 day market  average (mid price of the bid
and the ask) less a discount of 40%

2.  Pierpoint  would  require the  warrants  to be issued  against the first USD
225,000 as funds were  received  by Genomed  Inc.  and these  warrants  would be
possible to convert under the original offer terms  presented to GenoMed Inc. by
Pierpoint  and  accepted  by GenoMed on  February  5th 2004.  These terms are as
follows:

     (i) Pierpoint Investissements SA are eligible to purchase USD 225,000 worth
     of common,  12-month  restricted  shares in GenoMed  Inc. at USD 0.045 with
     warrants to match on the following terms: The warrants strike price will be
     fixed  at the 30 day  average  immediately  prior  to the  exercise  of the
     warrants less a discount of 50% with a 2 year expiry date from issue.

3. These warrants,  amounting to USD 225,000 / 0.045 or 5 million warrants,  are
to be  counted  against  the total of 40 million  warrants  which  Pierpoint  is
entitled by this  agreement,  leaving a second  category of 35 million  warrants
(see below)

<PAGE>

4.  The  second  point  of the  original  agreement  between  GenoMed  Inc.  and
Pierpoint, dated February 5th 2004 will also remain in effect. It is as follows:

     That upon funds being  received by GenoMed for the first  transaction as in
point (i) [now point #2(i) above] then Nikolas Piers Gilding will be eligible to
purchase  USD 250,000  worth of shares in GenoMed at USD 0.045 with  warrants to
match on the following  terms: The warrants strike price will be fixed at the 30
day average immediately prior to the exercise of the warrants less a discount of
50% with a 2 year expiry date from issue. Nikolas Gilding will have the right to
pay for his  shares  30  working  days  after  the  first  transaction  has been
completed.

5. These additional USD 250,000/ 0.045 or 5,555,556 warrants will not be counted
against the total of 40 million  warrants to which Pierpoint is entitled by this
agreement.

6. Mr.  Nikolas  Gilding  agrees to transfer  proxy  voting  power to  GenoMed's
management for a 12 month period after conversion to free-trading  shares of the
5,555,556 warrants mentioned in point #5 above.

7. For the remaining nine years  Pierpoint  would have to purchase a minimum USD
500,000 worth of GenoMed Inc. common,  12-month restricted shares each and every
year at the 30, day  market  average  (mid  price)  less a  discount  of 25% for
Pierpoint to be able to retain their rights to the remaining 35 million warrants
(see point #3)

8. The 35 million  warrants  would have an expiry date of 10 years from the date
of the revised offer being accepted by GenoMed Inc.  (Note:  the first 5 million
warrants have an expiry date of only 2 years). If Pierpoint failed to invest the
minimum  agreed amount of USD 500,000 per calendar year then they would lose all
their rights to all remaining unconverted warrants.

9. Apart from  Pierpoint's  5 million  warrants  mentioned  in point #2, and Mr.
Nikolas  Gilding's  5,555,556  warrants  mentioned in point #4, the remaining 35
million  warrants  covered  by this  agreement  (see  point  #3)  could  only be
converted  to  common,  12-month  restricted  shares if GenoMed  Inc.  stock was
trading at USD 1.00 or above. In other words, the warrants could be converted at
USD 0.60 (60  cents) if the 30 day  average  midpoint  of the bid and ask of the
stock was USD 1.00.  If the 30 day average  midpoint of the stock was, USD 0.99,
the warrants could not be converted.

10.  PIERPOINT WILL HAVE THE RIGHT TO EXERCISE ALL OF THEIR 35 MILLION  WARRANTS
WITHIN A 12 MONTH  PERIOD FROM WHEN  GENOMED  STOCK HAS TRADED AT LEAST USD 1.00
FOR 30 CONSECUTIVE TRADING DAYS AS IN POINT #9 ABOVE.

     (i) IF PIERPOINT CONVERTED / PLACED AT LEAST 20 MILLION OF THEIR 35 MILLION
     WARRANTS  WITHIN  THIS 12  MONTH  PERIOD,  THEN  THESE  CONVERTED  / PLACED
     WARRANTS  WOULD BE  REPLACED  WITH A FURTHER  40  MILLION  WARRANTS  WITH A
     10-YEAR  EXPIRY.  THESE  WARRANTS COULD BE EXERCISED AT A MAXIMUM RATE OF 8
     MILLION  WARRANTS PER YEAR OVER 5 YEARS.  THE EXERCISE  PRICE WILL BE A 50%
     DISCOUNT TO THE AVERAGE MARKET PRICE OF THE PREVIOUS 30' TRADING DAYS.

     (ii) IF, ON THE OTHER HAND,  PIERPOINT  WERE ABLE TO CONVERT / PLACE ALL 35
     MILLION WARRANTS WITHIN THE SAME 12 MONTH PERIOD, THEN THESE WARRANTS WOULD
     BE REPLACED WITH A FURTHER 80 MILLION WARRANTS WITH A 10-YEAR EXPIRY. THESE
     WARRANTS  COULD BE EXERCISED  AT A MAXIMUM RATE OF 16 MILLION  WARRANTS PER
     YEAR OVER 5 YEARS. THE EXERCISE PRICE WILL BE A 50% DISCOUNT TO THE AVERAGE
     MARKET PRICE OF THE PREVIOUS 30 TRADING DAYS.

11.  PROVIDING  THAT  PIERPOINT  MAINTAINED  THEIR USD  500,000  MINIMUM  ANNUAL
INVESTMENT INTO GENOMED THEN ALL ELIGIBLE WARRANTS WOULD REMAIN FULLY ACTIVE FOR
10 YEARS,  REGARDLESS OF WHETHER THEY HAD BEEN  CONVERTED INTO FULLY PAID SHARES
OR NOT.

PLEASE NOTE THE FOLLOWING, HOWEVER:

     (i) BECAUSE OF THE MAXIMUM  EXERCISE  RATE OF 8 MILLION  WARRANTS  PER YEAR
     [POINT #10(I)] OR 16 MILLION WARRANTS PER YEAR [POINT  #10(II)],  PIERPOINT
     MUST BEGIN  EXERCISING  ITS WARRANTS AT LEAST 5 YEARS PRIOR TO THEIR EXPIRY
     DATE.  OTHERWISE,  SOME OF PIERPOINT'S  WARRANTS WOULD EXPIRE WITHOUT BEING
     EXERCISABLE.

12. The calendar year referred to in this agreement ends on midnight,  local St.
Louis time on February  18th and begins anew at 12:01 am local St. Louis time on
February 19th

13. The 12-month restriction before sale on GenoMed's common stock begins at the
time of  conversion  of warrants  into common  stock,  not when the warrants are
issued.

14. As part of this  agreement,  Pierpoint  agrees  that no more than 10% of its
holdings in GenoMed  Inc. can be sold in any one month so as to avoid a negative
impact on GenoMed's share price. This requirement is passed on to any subsequent
owner of the warrants or shares of GenoMed Inc. covered by this agreement should
they be purchased, sold, or transferred to any additional parties.

15. This agreement expressly does not include the right of representation on the
Board of Directors of GenoMed Inc. by Pierpoint or any other investor in GenoMed
by virtue of this agreement.

16. None of the GenoMed Inc.  shares or warrants  referred to in this  agreement
can be hypothecated.

17.  GenoMed Inc.  shall be granted a 45 day right of first  refusal to purchase
any warrants or shares  (registered or  unregistered)  covered by this agreement
and  offered  for  sale  by  Pierpoint  or any of its  co-investors  under  this
agreement.

<PAGE>

18. This agreement shall be made under the laws of Missouri,  where GenoMed Inc.
is headquartered.

19. Pierpoint Investissements SA reserve the right to pay for and register their
shares through a private person / company / or Member Broker of their choice.

20. Finally,  it is understood that this transaction  involves  GenoMed's common
shares,  which are restricted  from sale for 12 months  according to Rule 144 of
the Securities and Exchange  Commission,  and that any  certificate  issued will
bear this legend.

Accepted


For GenoMed, Inc.                              For Pierpoint Investissements, SA

By


---------------------------------              ---------------------------------
David W. Moskowitz MD, CEO                     Nikolas Piers Gilding, Director

Date:                                          Date:
     ----------------------------                   ----------------------------

<PAGE>

From:    Dave Moskowitz [dwmoskowitz@genomedics.com]

Sent:    Tuesday, December 14, 2004 1:22 PM

To:      `Nikolas Piers Gilding'

Cc:      `Richard Kranitz'; `Robyn Owens'; pierre.banderet@bcp-bank.com

Subject: Pierpoint extension ...FINAL VERSION

Mr. Nikolas Piers Gilding
Director, Pierpoint Investissements SA Trident Chambers
P.O. Box 146
Tortola, British Virgin Islands


December 14th 2004


PIERPOINT INVESTISSEMENTS SA / GENOMED INC OFFER TERMS DATED JUNE 25TH 2004

Pierpoint  Investissements  SA current  offer terms with  GenoMed  Inc. are that
Pierpoint  has to  invest a minimum  of USD  500,000  up to a  maximum  of USD 2
million per year into GenoMed under the current offer terms.  The last date that
funds are due to GenoMed by Pierpoint  for the year 2004 / 2005 is February 18th
2005 close of business.

This  e-mail / letter  serves to confirm  that  Pierpoint  have been  granted an
extension  from  February  18th 2005 until  April 2nd 2005 close of  business to
complete their year 2004 / 2005 minimum USD 500,000 investment into GenoMed,  in
return for Pierpoint paying GenoMed a non-refundable  amount of USD 10,000. This
amount is intend solely to extend the deadline for the first year of investment,
and is not intended to purchases any shares in GenoMed.

Sincerely yours,


Dave Moskowitz MD

CEO, GenoMed Inc.

cc: Robyn Owens, CFO

Richard Kranitz, Secretary, Board of Directors

Pierre Banderet, BCP Bank